IL166269A0 - A pharmaceutical composition containing an activated form of diluted antibodies to ?-tnf - Google Patents

A pharmaceutical composition containing an activated form of diluted antibodies to ?-tnf

Info

Publication number
IL166269A0
IL166269A0 IL16626905A IL16626905A IL166269A0 IL 166269 A0 IL166269 A0 IL 166269A0 IL 16626905 A IL16626905 A IL 16626905A IL 16626905 A IL16626905 A IL 16626905A IL 166269 A0 IL166269 A0 IL 166269A0
Authority
IL
Israel
Prior art keywords
tnf
pharmaceutical composition
composition containing
activated form
diluted antibodies
Prior art date
Application number
IL16626905A
Other languages
English (en)
Original Assignee
Evgeny Danilovich Goldberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evgeny Danilovich Goldberg filed Critical Evgeny Danilovich Goldberg
Publication of IL166269A0 publication Critical patent/IL166269A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16626905A 2002-08-02 2005-01-06 A pharmaceutical composition containing an activated form of diluted antibodies to ?-tnf IL166269A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2002/000367 WO2004012766A1 (fr) 2002-08-02 2002-08-02 Procede de correction de reactions immunitaires pathologiques et preparation medicinale

Publications (1)

Publication Number Publication Date
IL166269A0 true IL166269A0 (en) 2006-01-15

Family

ID=31492975

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16626905A IL166269A0 (en) 2002-08-02 2005-01-06 A pharmaceutical composition containing an activated form of diluted antibodies to ?-tnf

Country Status (7)

Country Link
US (3) US20060153845A1 (ru)
EP (1) EP1550460A4 (ru)
AU (1) AU2002325433A1 (ru)
EA (1) EA008605B1 (ru)
IL (1) IL166269A0 (ru)
UA (1) UA76640C2 (ru)
WO (1) WO2004012766A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) * 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (ru) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Способ коррекции патологических иммунных реакций и гомеопатическое лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2010134086A1 (en) * 2009-05-19 2010-11-25 Rajesh Shah Medicinal formulation containing selected cytokines
US8974771B2 (en) * 2010-03-09 2015-03-10 Penn-Century, Inc. Apparatus and method for aerosol delivery to the lungs or other locations of the body
SG10201505561TA (en) 2010-07-15 2015-08-28 Oleg Iliich Epshtein A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
ITTO20110641A1 (it) * 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
AU2011278032B2 (en) * 2010-07-15 2015-07-23 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
DE112011102362T5 (de) 2010-07-15 2013-04-25 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
JP2013535444A (ja) 2010-07-21 2013-09-12 イリイチ・エプシテイン オレグ 注意欠陥多動性障害を治療する方法
GB2503066B8 (en) * 2010-08-06 2019-03-13 Iliich Epshtein Oleg Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2535033C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
DE202013011988U1 (de) 2012-05-15 2015-04-01 Rajesh Shah Entzündungshemmende Rezeptur
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4987127A (en) * 1989-01-31 1991-01-22 Dal Sirany Method of treating a virus outbreak
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5741488A (en) * 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
US5879677A (en) * 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
IT1261849B (it) * 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
JP3696884B2 (ja) * 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
WO1997039772A1 (fr) * 1996-04-19 1997-10-30 Chugai Seiyaku Kabushiki Kaisha Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76640C2 (ru) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Способ коррекции патологических иммунных реакций и гомеопатическое лекарственное средство

Also Published As

Publication number Publication date
AU2002325433A8 (en) 2004-02-23
AU2002325433A1 (en) 2004-02-23
US20140010819A1 (en) 2014-01-09
WO2004012766A1 (fr) 2004-02-12
WO2004012766A8 (fr) 2005-03-03
UA76640C2 (ru) 2006-08-15
EP1550460A1 (en) 2005-07-06
EA200500101A1 (ru) 2005-08-25
US20070141058A1 (en) 2007-06-21
EP1550460A4 (en) 2006-03-22
EA008605B1 (ru) 2007-06-29
US20060153845A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
IL166269A0 (en) A pharmaceutical composition containing an activated form of diluted antibodies to ?-tnf
IL166656A0 (en) A pharmaceutical composition containing an activated form of ultra small doses of antibodies to interferon
TWI365883B (en) Antibodies to m-csf
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
EP1535930A4 (en) FOR THE CENTRAL TETRA PROTEIN SPECIFIC ANTIBODY
IL163667A0 (en) Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
IL158493A0 (en) Pharmaceutical compositions containing venlafaxine
EP1712240A4 (en) STABLE MEDICAL WATER BASED PREPARATION WITH ANTIBODY
AU2003221604A8 (en) Use of an active substance that binds to cd28 for producing a pharmaceutical composition
IL179933A0 (en) Pharmaceutical compositions containing proteosome based compositions
IL173639A (en) Ppar-activating compound and pharmaceutical composition containing same
AU2003291103A8 (en) Pharmaceutical composition
EP1664627A4 (en) FUNCTIONAL APPLICATION OF PHOTOCHROME CONNECTING MATERIALS TO PRODUCTS
ZA200508204B (en) Pharmaceutical composition of atorvastatin
IL164547A0 (en) Pharmaceutical composition
AU2003250372A8 (en) Pharmaceutical composition
EP1723970A4 (en) MEDICAL COMPOSITION WITH CXCR3 INHIBITOR
AU2003245033A1 (en) An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
HK1065477A1 (en) Pharmaceutical composition
AU2003274655A8 (en) Pharmaceutical compositions containing venlafaxine
HU0200337D0 (en) Stabilised pharmaceutical composition
IL152397A0 (en) Development of novel anti-hyperglycemic drugs
HUP0201288A3 (en) New pharmaceutical composition of docetaxel
GB0227595D0 (en) Ready to drink medicines
SI1661890T1 (sl) Spojina, ki aktivira PPAR, in farmacevtski sestavek, ki jo vsebuje